ArticleEMBO molecular medicine2022
External validity in translational biomedicine: understanding the conditions enabling the cause to have an effect.
Article in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- How to Foster Challenging Interdisciplinary Collaborations: Can Philosophy Support Neuroscientists?The European journal of neuroscience · 2026Review
- Perspective on the integration of radiomics and spatial omics in the analysis of the tumor microenvironment of bladder cancer and prospects for precision diagnosis and treatment.Frontiers in immunology · 2026Review
- [3D printing in surgery: relevance of technology maturity assessment in bioprinting research studies].Chirurgie (Heidelberg, Germany) · 2025Review
- Mosquitoes Reared in Nearby Insectaries at the Same Institution Have Significantly Divergent Microbiomes.Environmental microbiology · 2025Article
- Mosquitoes reared in distinct insectaries within an institution in close spatial proximity possess significantly divergent microbiomes.bioRxiv : the preprint server for biology · 2024Article
- Cognitions in antisocial personality and their association with "dark" traits.Scientific reports · 2024Article
- Protocol for the systematic review of age and sex in preclinical models of age-correlated diseases.F1000Research · 2024Article
- What are the chances? Clinician scientist` career pathways in Germany.BMC medical education · 2023Article
- Article
- External validity in translational biomedicine: understanding the conditions enabling the cause to have an effect.EMBO molecular medicine · 2022Article
- Quality of reporting and adherence to the ARRIVE guidelines 2.0 for preclinical degradable metal research in animal models of bone defect and fracture: a systematic review.Regenerative biomaterials · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A spectre is haunting biomedical research: It appears that a substantial fraction of published research results cannot be reproduced, while spectacularly successful novel treatments developed in experimental models of disease too often fail in clinical trials. A reproducibility crisis has been proclaimed, and bench-to-bedside translation appears to be lost in a "valley of death". Both predicaments, non-reproducibility and translational roadblocks, are connected: Why should we expect to successfully "trans-late" results to humans, if already "cis-lation"-that is, the generalization from one experimental setting to an identical or fairly similar one-often fails?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.